Gilead Q3 revenue rise bolstered by $873m Veklury salesGilead Sciences is the first and so far only company to claim FDA approval for a COVID-19 treatment Share XGilead Q3 revenue rise bolstered by $873m Veklury saleshttps://pharmaphorum.com/news/gilead-q3-revenue-rise-bolstered-by-873m-veklury-sales/
Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabiliseNovartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new Share XNovartis CEO thinks 2nd health lockdown unlikely, as Q3 sales stabilisehttps://pharmaphorum.com/news/novartis-ceo-thinks-2nd-health-lockdown-unlikely-as-q3-sales-stabilise/
CureVac claims €75m in EU funding for mRNA COVID-19 vaccineGerman vaccine firm CureVac has been awarded a €75 million loan from the European Investment Bank to boost Share XCureVac claims €75m in EU funding for mRNA COVID-19 vaccinehttps://pharmaphorum.com/news/curevac-claims-e75m-in-eu-funding-for-mrna-covid-19-vaccine/
Royalty Pharma shares surge 59% after $2.2 billion IPOBiopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised Share XRoyalty Pharma shares surge 59% after $2.2 billion IPOhttps://pharmaphorum.com/news/royalty-pharma-shares-surge-59-after-2-2-billion-ipo/
Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel fileThe chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right Share XCelgene investors’ CVR payment looks rocky, as FDA rejects ide-cel filehttps://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/
COVID-19 candidate Actemra helps Roche to solid first quarterRoche shrugged off the impact of the coronavirus pandemic in the first-quarter with good sales growth across its Share XCOVID-19 candidate Actemra helps Roche to solid first quarterhttps://pharmaphorum.com/news/covid-19-candidate-actemra-helps-roche-to-solid-first-quarter/
Bill Gates slams Trump move to cut WHO funding over coronavirusUnder fire over his response to the coronavirus epidemic, President Donald Trump has launched a diversionary attack, withdrawing Share XBill Gates slams Trump move to cut WHO funding over coronavirushttps://pharmaphorum.com/news/bill-gates-slams-trump-move-to-cut-who-funding-over-coronavirus/
J&J lowers 2020 forecast on COVID-19 uncertaintyJohnson & Johnson has kicked off the first-quarter results season with a healthy lift in sales and earnings, Share XJ&J lowers 2020 forecast on COVID-19 uncertaintyhttps://pharmaphorum.com/news/jj-lowers-2020-forecast-on-covid-19-uncertainty/
Takeda eyes emerging markets asset sale to trim its debt; reportTakeda is said to be considering the sale of assets in emerging markets and western Europe to pay Share XTakeda eyes emerging markets asset sale to trim its debt; reporthttps://pharmaphorum.com/news/takeda-eyes-emerging-markets-asset-sale-to-trim-its-debt-report/
